Adlai Nortye

About:

Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.

Top Investors: Matrix Partners China, Legend Star, DT Capital Partners, Yingke Capital, WuXi Healthcare Ventures

Description:

Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development.

Total Funding Amount:

$293M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Hangzhou, Zhejiang, China

Founded Date:

2016-01-01

Contact Email:

info(AT)adlainortye.com

Founders:

Carsten Lu

Number of Employees:

51-100

Last Funding Date:

2023-09-29

IPO Status:

Public

Industries: